# Opportunities in Unified Agentic and Generative AI for Oncology Trials

## Overview

Unifying agentic AI frameworks across oncology clinical trial sites
creates opportunities that transcend the capabilities of any single
orchestration platform. The combination of multi-agent collaboration,
federated learning, and clinical domain knowledge produces compounding
advantages for patient outcomes, operational efficiency, and
regulatory compliance.

---

## 1. Cross-Institutional Knowledge Synthesis

### 1.1 Federated Literature Agents

Literature review agents at different institutions can specialize in
different knowledge domains:

- Site A's agent focuses on immunotherapy clinical outcomes
- Site B's agent specializes in surgical robotics literature
- Site C's agent covers radiation oncology protocols

A unified interface allows these agents to share structured findings
without exposing proprietary search strategies or institutional
knowledge bases. The aggregated knowledge exceeds what any single
site can produce.

### 1.2 Multi-Site Adverse Event Pattern Detection

Adverse events that are rare at a single site may become statistically
significant when aggregated across the federation. Unified agent
interfaces enable:

- Standardized adverse event classification (MedDRA coding)
- Cross-site temporal pattern analysis
- Automated signal detection that respects data sovereignty

### 1.3 Protocol Harmonization

When different sites use different agentic frameworks to generate
protocol sections, a unified interface ensures that outputs conform
to a common structure (ICH-E6 GCP format), enabling automated
consistency checking across the federation.

---

## 2. Specialized Agent Ensembles

### 2.1 Virtual Tumor Board

A unified agent interface enables construction of a virtual tumor
board where specialized agents from different frameworks collaborate:

| Agent Role | Optimal Framework | Rationale |
|------------|------------------|-----------|
| Oncologist | LangGraph | Complex reasoning with branching decision trees |
| Radiologist | CrewAI | Sequential image analysis pipeline |
| Pathologist | AutoGen | Collaborative dialogue for differential diagnosis |
| Pharmacist | Custom | Institutional formulary integration |

Each agent uses its optimal framework while communicating through the
unified interface.

### 2.2 Treatment Planning Optimization

Multi-agent treatment planning can explore more options than single-agent
approaches:

1. **Exploration agent** (CrewAI): Generates candidate treatment plans
   from clinical guidelines and literature
2. **Simulation agent** (LangGraph): Evaluates candidates using patient
   digital twin simulation
3. **Safety agent** (AutoGen): Validates plans against contraindications
   and drug interactions
4. **Optimization agent** (Custom): Selects the Pareto-optimal plan
   balancing efficacy, toxicity, and patient preference

### 2.3 Adaptive Trial Design

Agents can monitor trial progress and recommend protocol amendments:

- Enrollment rate analysis and projection
- Interim efficacy analysis with futility boundaries
- Safety monitoring with automated DSMB reporting

The unified interface ensures these agents work consistently regardless
of which institution hosts them.

---

## 3. Regulatory Automation

### 3.1 Automated Compliance Checking

A unified agent interface enables compliance-checking agents that
operate across all institutional boundaries:

- Verify that every data access is logged per 21 CFR Part 11
- Ensure consent records match data usage per HIPAA
- Validate that model updates comply with the trial's statistical
  analysis plan

### 3.2 Submission Package Generation

FDA submission packages require extensive documentation. Unified
agents can:

- Auto-generate device description documents from code and configs
- Compile performance testing results from cross-platform validation
- Draft risk analysis documents from safety test outcomes
- Prepare 510(k) summary documents with standardized formatting

### 3.3 Post-Market Surveillance Automation

After device clearance, agents can continuously monitor:

- Published literature for relevant safety signals
- MAUDE database for related adverse events
- Real-world performance data from deployed devices

---

## 4. Operational Efficiency

### 4.1 Reduced Development Time

Institutions do not need to rewrite their agentic workflows when
joining the federation. The unified interface adapts existing
CrewAI/LangGraph/AutoGen deployments with minimal code changes.

### 4.2 Shared Tool Ecosystem

Clinical trial tools (DICOM viewers, FHIR clients, genomics
databases, drug interaction checkers) can be implemented once and
shared across all frameworks via the unified tool interface. This
eliminates redundant tool development across sites.

### 4.3 Centralized Monitoring

A unified agent interface enables a federation-wide monitoring
dashboard that tracks:

- Agent invocation counts and latencies across all sites
- Tool call success/failure rates
- LLM token usage and cost per site
- Compliance audit trail completeness

---

## 5. Research Acceleration

### 5.1 Reproducible Agent Benchmarks

A common interface enables standardized benchmarks for clinical
agent performance:

- Medical question answering accuracy (vs. board-certified experts)
- Protocol generation quality (ICH-GCP compliance score)
- Adverse event detection sensitivity and specificity
- Treatment recommendation concordance with NCCN guidelines

### 5.2 Cross-Framework Ablation Studies

Researchers can test whether a specific agentic workflow performs
better on CrewAI vs. LangGraph vs. AutoGen, isolating the framework
effect from the algorithm effect. This produces actionable knowledge
about which framework suits which clinical task.

### 5.3 Novel Collaboration Patterns

The unified interface enables collaboration patterns that are
impossible within a single framework:

- **Cross-institutional debate**: Agents at different sites debate
  a clinical question, each grounded in local (non-shared) data
- **Federated consensus**: Agents vote on a recommendation, each
  weighted by site-specific evidence strength
- **Hierarchical review**: Junior agents propose, senior agents
  review, attending agents approve -- mirroring clinical hierarchy

---

## 6. Patient-Facing Applications

### 6.1 Personalized Education

Unified agents can provide patients with personalized education
about their treatment plan, drawing on the full federation's
knowledge while respecting institutional communication preferences.

### 6.2 Symptom Monitoring

Agents can monitor patient-reported outcomes via chatbot interfaces,
with the underlying framework chosen based on the specific monitoring
protocol (acute toxicity monitoring vs. long-term follow-up).

### 6.3 Clinical Trial Matching

Multi-agent systems can match patients to appropriate trials by:

1. Parsing eligibility criteria from ClinicalTrials.gov
2. Matching against patient electronic health records
3. Ranking trials by expected benefit and proximity
4. Presenting options to the treating oncologist

---

## Summary

The unified agentic AI interface transforms fragmented institutional
AI investments into a cohesive, federation-wide intelligence layer.
The key opportunities -- cross-institutional knowledge synthesis,
specialized agent ensembles, regulatory automation, and research
acceleration -- create a platform whose aggregate capability
significantly exceeds the sum of its parts.
